Regimens for Drug-Resistant Tuberculosis

To the Editor: Conradie et al. (Sept. 1 issue) 1 report impressive results of the ZeNix trial of a bedaquiline–pretomanid–linezolid regimen for drug-resistant tuberculosis, with doses of linezolid that were lower than the 1200-mg dose that has been associated with adverse events. In this trial perfo...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 2; pp. 189 - 191
Main Authors Perumal, Rubeshan, Nimmo, Camus, O’Donnell, Max, Lange, Christoph, Köhler, Niklas, Günther, Gunar, Timm, Juliano, Crook, Angela M., Sun, Eugene
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 12.01.2023
Subjects
Clinical outcomes
Conflicts of interest
Diarylquinolines
Drug dosages
Drug resistance
Humans
Linezolid
Minimum inhibitory concentration
Multidrug resistant organisms
Mutation
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
United Kingdom > UK
New York
United States > US
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Conradie et al. (Sept. 1 issue) 1 report impressive results of the ZeNix trial of a bedaquiline–pretomanid–linezolid regimen for drug-resistant tuberculosis, with doses of linezolid that were lower than the 1200-mg dose that has been associated with adverse events. In this trial performed in South Africa, the country of Georgia, Moldova, and Russia, 9 of the 181 participants (5.0%) had bedaquiline resistance (minimum inhibitory concentration, 2 to 4 μg per milliliter) at baseline. Despite reported 99.8% adherence to the trial regimen, 6 of 9 participants (67%) with bedaquiline-resistant tuberculosis at baseline had a favorable outcome, as compared with . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2213970